公司资料
Puma Biotechnology Inc 股价、新闻与催化剂
- 股票代码:
- PBYI
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
9.84 USD (-0.91%)
收盘价
最后更新: 2026年10月1日
355M USD
市值
股价为何变动
截至 2026年10月1日，PBYI 下跌 0.91%，收于 $9.84。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Commercial Oncology Company
Puma Biotechnology develops and commercializes therapies for breast cancer and other solid tumors. Its business combines the established NERLYNX franchise with clinical development of the Aurora kinase A inhibitor alisertib.
NERLYNX in HER2-Positive Breast Cancer
NERLYNX, or neratinib, is an oral irreversible pan-HER kinase inhibitor. It is approved as extended adjuvant treatment after trastuzumab-based therapy in early-stage HER2-positive breast cancer and with capecitabine in previously treated advanced or metastatic HER2-positive disease.
U.S. Commercial and International Royalty Model
Puma directly markets NERLYNX in the United States and supports access through its Patient Lynx program. International partners commercialize neratinib in other territories, providing Puma with royalty and licensing revenue.
Alisertib Development Program
Alisertib is an oral, selective inhibitor of Aurora kinase A, a protein involved in mitotic progression. Puma licensed global development and commercialization rights and is initially focusing the program on small cell lung cancer and hormone receptor-positive, HER2-negative metastatic breast cancer.
ALISCA Clinical Portfolio
ALISCA-Lung1 evaluates alisertib monotherapy in extensive-stage small cell lung cancer, while ALISCA-Lung2 evaluates alisertib with paclitaxel. ALISCA-Breast1 combines alisertib with endocrine therapy in chemotherapy-naive metastatic breast cancer.
未来催化剂
- Initiation of enrollment in the ALISCA-Lung2 Phase 1/2 trial in the third quarter of 2026.
- Enrollment expansion in ALISCA-Lung1 and ALISCA-Breast1 in the second half of 2026.
- Updated Phase 2 data from ALISCA-Breast1 in the fourth quarter of 2026.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。